Niki BioSolutions, Inc. (NIKI)
| Market Cap | $4.68M-88.9% |
| Revenue (ttm) | n/a |
| Net Income | -$2.25M |
| EPS | -$2.90 |
| Shares Out | 2.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,987 |
| Open | $1.71 |
| Previous Close | $1.70 |
| Day's Range | $1.50 - $1.71 |
| 52-Week Range | $1.42 - $17.20 |
| Beta | -0.80 |
| Analysts | none |
| Price Target | n/a |
| Earnings Date | n/a |
About NIKI
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule, which is in a preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule, which is in a preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule, which is in a preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as Aptorum Group Limited and changed its name to Niki BioSolutions, Inc. in July 2026. Niki BioSolutions, Inc. was incorporated in 2010 and is headquartered in Princeton, New Jersey. Niki BioSolutions, Inc. operates as a subsidiary of Jurchen Investment Corporation.
$NIKI stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in NIKI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NIKI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NIKI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New NIKI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NIKI from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from NIKI’s recent data — informational, not investment advice
